BASES MOLECULARES DE LA ESQUIZOFRENIA
445
60.
Zafra, F.; Aragón, C.; Olivares, L.; Danbolt, N.C.; Giménez, C. & Storm-‐Mathisen, J. (1995)
Glycine transporters are differentially expressed among CNS cells. Journal of
Neuroscience 15, 3952-‐3969.
61.
Zafra, F.; Gomeza, J.; Olivares, L.; Aragón, C. & Giménez, C. (1995) Regional distribution
and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS.
European Journal of Neuroscience 7, 1342-‐1352.
62.
Cubelos, B.; Giménez, C. & Zafra, F. (2005) Localization of the GLYT1 glycine transporter at
glutamatergic synapses in the rat brain. Cerebral Cortex 15, 448-‐459.
63.
Cubelos, B.; González-‐González, I.M.; Giménez, C. & Zafra, F. (2005) The scaffolding protein
PSD-‐95 interacts with the glycine transporter GLYT1 and impairs its internalization.
Journal of Neurochemistry 95, 1047-‐1058.
64.
González-‐González, I. M.; García-‐Tardón, N.; Cubelos, B.; Giménez, C. & Zafra, F. (2008) The
glutamate transporter GLT1b interacts with the scaffold protein PSD-‐95. Journal of
Neurochemistry 105, 1834-‐1848.
65.
Krystal, J.H.; Anand, A. & Moghaddam, B. (2002) Effects of NMDA receptor
antagonists:implications for the pathophysiology of schizophrenia. Archives of General
Psychiatry 59, 663-‐664.
66.
Abi-‐Saab, W.M.; D'Souza, D. C.; Moghaddam, B. & Krystal, J. H. (1998) The NMDA
antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 31
Suppl2,104-‐109.
67.
Krystal, J.H.; Karper, L. P.; Seibyl, J. P.; Freeman, G. K.; Delaney, R.; Bremner, J. D.; Heninger,
G. R.; Bowers, M. B. Jr. & Charney, D. S. (1994) Subanesthetic effects of the noncompetitive
NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and
neuroendocrine responses. Archives of General Psychiatry 51, 199-‐214.
68.
Sur, C. & Kinney, G. G. (2007) Glycine transporter 1 inhibitors and modulation of NMDA
receptor-‐mediated excitatory neurotransmission. Current Drug Target 8, 643-‐649.
69.
Lindsley, C. W.; Zhao, Z.; Leister, W. H.; O'Brien, J.; Lemaire, W.; Williams. D. L. Jr.; Chen, T.
B.; Chang, R, S.; Burno, M.; Jacobson, M. A.; Sur, C.; Kinney, G. G.; Pettibone, D. J.; Tiller, P. R.;
Smith, S.; Tsou, N. N.; Duggan, M. E., Conn, P. J. & Hartman, G. D. (2006) Design, synthesis,
and in vivo efficacy of glycine transporter-‐1 (GlyT1) inhibitors derived from a series of[4-‐
phenyl-‐1-‐(propylsulfonyl)piperidin-‐4-‐yl]methylbenzamides. Chemical Medicine 8, 807-‐
811.
70.
Rogers, B. N. & Schmidt, C. J. (2006) Novel approaches for the treatment of schizophrenia.
Annual Reports in Medicinal Chemistry 41, 1-‐21.
71.
Sur, C. & Kinney, G. (2007) Glycine transporter 1 inhibitors and modulation of NMDA
receptor-‐mediated excitatory neurotransmission. Current Drug Targets 8, 643-‐649.
72.
Dohi, T.; Morita, K.; Kitiyama, T.; Motoyama, N. & Morioka, N. (2009) Glycine transporter
inhibitors as a novel drug discovery strategy for neuropathic pain. Pharmacology and
Terapeuthics 123, 54-‐79.
